ReviewBreast cancer : basic and clinical research2021
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches.
Review in Breast cancer : basic and clinical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial Intelligence for Breast Cancer Molecular Subtype Prediction From Medical Imaging: A Systematic Review of Literature.Technology in cancer research & treatmentPooled it
- Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Randomized Controlled Trial.JCO global oncology · 2024Trial
- Multifunctional Nanoparticles Fabricated by Dispersion Polymerization for the Treatment of Triple-Negative Breast Cancer.Journal of biomedical nanotechnology · 2026Article
- Unlocking new therapeutic horizons through integrative bioinformatics and transcriptomics for drug repositioning in breast cancer therapy.Journal of the Egyptian National Cancer Institute · 2026Article
- Coumarin Derivatives as Anticancer Agents: Mechanistic Landscape with an Emphasis on Breast Cancer.Molecules (Basel, Switzerland) · 2025Review
- Evaluation of CircHIPK3 biomarker potential in breast cancer.Practical laboratory medicine · 2025Article
- LMNB1 regulates breast cancer cell senescence and migration through PPAR signaling pathway.Discover oncology · 2025Article
- Epidemiological and molecular profile of breast cancer: a retrospective study in Casablanca, Morocco.The Pan African medical journal · 2025Article
- Tumor-derived extracellular vesicles mediate cell-specific uptake and facilitate enhanced doxorubicin delivery in breast cancer.Frontiers in pharmacology · 2025Article
- Autophagy as a Therapeutic Target in Breast Tumors: The Cancer stem cell perspective.Autophagy reports · 2024Article
- Caveolin-1 knockout mitigates breast cancer metastasis to the lungs via integrin α3 dysregulation in 4T1-induced syngeneic breast cancer model.Cancer gene therapy · 2024Article
- Article
- A Comprehensive Review of Nanoparticles: From Classification to Application and Toxicity.Molecules (Basel, Switzerland) · 2024Review
- Review
- Chlorin Conjugates in Photodynamic Chemotherapy for Triple-Negative Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Molecular docking analysis of pyrrole derivatives with different breast cancer targets.Bioinformation · 2024Article
- Integration of transcriptomics and machine learning for insights into breast cancer: exploring lipid metabolism and immune interactions.Frontiers in immunology · 2024Article
- Multiplex electrochemical sensing platforms for the detection of breast cancer biomarkers.Frontiers in medical technology · 2024Review
- Androgen Receptor Expression in ER and PR Negative Breast Cancer-A Study from a Tertiary Hospital in Northern India.South Asian journal of cancer · 2023Article
- Developing multitarget coumarin based anti-breast cancer agents: synthesis and molecular modeling study.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the leading cause of cancer death in women and the second-most common cancer. An estimated 281 550 new cases of invasive BC will be diagnosed in women in the United States, and about 43 600 will die during 2021. Continual research has shed light on all disease areas, including tumor classification and biomarkers for diagnosis/prognosis. As research investigations evolve, new classes of drugs are emerging with potential benefits in BC treatment that are covered in this manuscript. The initial sections present updated classification and terminology used for diagnosis and prognosis, which leads to the following topics, discussing the past and present treatments available for BC. Our review will generate interest in exploring the complexity of the cell cycle and its association with cancer biology as part of the plethora of target factors toward developing newer drugs and effective therapeutic management of BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.